BiomX completes patient enrollment in BX001 study

BiomX announced that patient recruitment for its cosmetic clinical study of BX001, initiated on October 1, is complete and that 75 patients have been recruited. BX001 is a topically administered gel comprised of a cocktail of naturally occurring phage targeting Cutibacterium acnes, a bacterium implicated in the pathophysiology of acne vulgaris. The primary endpoints of the randomized, double-blind, dose-ranging, vehicle-controlled study are safety and tolerability. Exploratory endpoints include proof of principle by measurement of the effect of BX001 on C. acnes levels. Data from this trial are expected at the end of the first quarter of 2020. BiomX enrolled 75 individuals with mild-to-moderate acne in the ongoing cosmetic clinical study of BX001. Enrolled individuals were randomized into three cohorts: a higher-dose cohort, a lower dose cohort and a placebo cohort. For BX001 studies in acne-prone skin, BiomX is working in collaboration with a multinational cosmetic company.